Arielle Crestol , Dennis van der Meer , Nadine Parker , Ann-Marie de Lange , Espen Hagen , Hannah Oppenheimer , Stener Nerland , Edith Breton , Christian K Tamnes , Ole A. Andreassen , Ingrid Agartz , Claudia Barth
{"title":"THE ROLE OF SEX IN POLYGENIC RISK FOR SEX-BIASED BRAIN DISORDERS","authors":"Arielle Crestol , Dennis van der Meer , Nadine Parker , Ann-Marie de Lange , Espen Hagen , Hannah Oppenheimer , Stener Nerland , Edith Breton , Christian K Tamnes , Ole A. Andreassen , Ingrid Agartz , Claudia Barth","doi":"10.1016/j.euroneuro.2025.08.552","DOIUrl":null,"url":null,"abstract":"<div><div>Sex differences in genetic vulnerability have been implicated in psychiatric and neurodegenerative disorders, yet their specific impact on brain health and clinical risk remains poorly understood. Leveraging data from up to 220,836 women and 187,651 men from the UK Biobank (aged 39–81), we assessed how sex and polygenic risk scores (PRSs) for major depressive disorder (PRSMDD), Alzheimer’s disease (PRSAD), schizophrenia (PRSSCZ), and Parkinson’s disease (PRSPD) relate to case-control status and brain age gap (BAG), a neuroimaging marker of brain health. We tested for sex differences in PRSs and performed regression analyses examining associations between sex, PRSs, and either case-control status or BAG. We then compared models with sex-pooled and sex-specific PRSs to explore whether sex-specific PRSs can improve predictive accuracy. While PRSSCZ was higher in women compared to men, no other sex differences were found between PRSs. Our most striking finding was a significant PRSAD-by-sex interaction, in which PRSAD conferred greater risk for AD diagnosis in women compared to men. Consistently, the women-only PRSAD model outperformed the sex-pooled model, while no differences were observed between sex-pooled and men-only models. By contrast, sex-pooled PRS models outperformed sex-specific PRS models for MDD, SCZ, and PD. No sex-by-PRS interactions were significantly associated with BAG. However, men presented with higher BAG values than women, indicative of an older brain age. Further, higher PRSMDD, higher PRSAD, and lower PRSPD were each associated with higher BAG, irrespective of sex. Finally, BAG model performance did not differ between sex-pooled and sex-specific PRS models. Our findings highlight that sex moderates AD genetic risk for diagnostic status in middle-to-late-life adults, and as such, tailoring PRSs by sex may improve risk assessment for AD. While sex-specific PRSs offered limited value for the other disorders, our findings suggest that the value of sex-specific PRSs will likely grow with increased statistical power.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"99 ","pages":"Page 48"},"PeriodicalIF":6.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X25007102","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Sex differences in genetic vulnerability have been implicated in psychiatric and neurodegenerative disorders, yet their specific impact on brain health and clinical risk remains poorly understood. Leveraging data from up to 220,836 women and 187,651 men from the UK Biobank (aged 39–81), we assessed how sex and polygenic risk scores (PRSs) for major depressive disorder (PRSMDD), Alzheimer’s disease (PRSAD), schizophrenia (PRSSCZ), and Parkinson’s disease (PRSPD) relate to case-control status and brain age gap (BAG), a neuroimaging marker of brain health. We tested for sex differences in PRSs and performed regression analyses examining associations between sex, PRSs, and either case-control status or BAG. We then compared models with sex-pooled and sex-specific PRSs to explore whether sex-specific PRSs can improve predictive accuracy. While PRSSCZ was higher in women compared to men, no other sex differences were found between PRSs. Our most striking finding was a significant PRSAD-by-sex interaction, in which PRSAD conferred greater risk for AD diagnosis in women compared to men. Consistently, the women-only PRSAD model outperformed the sex-pooled model, while no differences were observed between sex-pooled and men-only models. By contrast, sex-pooled PRS models outperformed sex-specific PRS models for MDD, SCZ, and PD. No sex-by-PRS interactions were significantly associated with BAG. However, men presented with higher BAG values than women, indicative of an older brain age. Further, higher PRSMDD, higher PRSAD, and lower PRSPD were each associated with higher BAG, irrespective of sex. Finally, BAG model performance did not differ between sex-pooled and sex-specific PRS models. Our findings highlight that sex moderates AD genetic risk for diagnostic status in middle-to-late-life adults, and as such, tailoring PRSs by sex may improve risk assessment for AD. While sex-specific PRSs offered limited value for the other disorders, our findings suggest that the value of sex-specific PRSs will likely grow with increased statistical power.
期刊介绍:
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.